{{Rsnum
|rsid=2242330
|Gene=STAP1
|Chromosome=4
|position=67581531
|Orientation=minus
|GMAF=0.2025
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=STAP1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 7.1 | 34.5 | 58.4
| HCB | 8.0 | 33.6 | 58.4
| JPT | 2.7 | 21.2 | 76.1
| YRI | 1.4 | 18.4 | 80.3
| ASW | 3.5 | 21.1 | 75.4
| CHB | 8.0 | 33.6 | 58.4
| CHD | 6.4 | 36.7 | 56.9
| GIH | 5.9 | 47.5 | 46.5
| LWK | 1.8 | 17.3 | 80.9
| MEX | 1.7 | 12.1 | 86.2
| MKK | 2.6 | 20.5 | 76.9
| TSI | 6.9 | 44.1 | 49.0
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs2242330
|PubMedID=17052657
|Condition=Parkinson's disease
|Gene=BRDG1
|Risk Allele=
|pValue=2.00E-006
|OR=2
|95CI=1.43-2.50
}}

{{PharmGKB
|RSID=rs2242330
|Name_s=
|Gene_s=STAP1
|Feature=
|Evidence=PubMed ID:17052657; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data (Initial Sample Size: 267 cases, 270 controls; Replication Sample Size: NR). This variant is associated with Parkinson's disease.
|Drugs=
|Drug Classes=
|Diseases=Parkinson Disease
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356539
}}

{{PMID|20369022|OA=1
}} Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2242330
|overall_frequency_n=27
|overall_frequency_d=128
|overall_frequency=0.210938
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=23
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}